Comparative Pharmacology
Head-to-head clinical analysis: ETHACRYNATE SODIUM versus TORSEMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHACRYNATE SODIUM versus TORSEMIDE.
ETHACRYNATE SODIUM vs TORSEMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ethacrynate sodium inhibits the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased diuresis.
Torsemide inhibits the Na+/K+/2Cl- cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing sodium, chloride, and water reabsorption, leading to increased urine output and decreased extracellular fluid volume.
50 mg intravenously once daily; may increase in increments of 25-50 mg as needed, maximum 200 mg/day.
Oral or intravenous: 5-20 mg once daily; may titrate up to 40 mg daily. Usual maintenance: 5-10 mg daily.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in normal renal function; prolonged to 20-30 hours in end-stage renal disease.
Terminal elimination half-life is 3-4 hours in healthy adults; prolonged to 4-8 hours in cirrhosis and with advanced age. In renal failure (CrCl <30 mL/min), half-life may exceed 8 hours.
Renal: approximately 30% unchanged; biliary/fecal: minor (less than 10%); majority metabolized to cysteine adducts excreted in urine.
Approximately 80% renal (20% unchanged, 60% as metabolites, mainly glucuronide conjugate), 20% biliary/fecal. In renal impairment, clearance is reduced and half-life prolonged.
Category C
Category A/B
Loop Diuretic
Loop Diuretic